Vitiligo: Where Do We Stand?

Pigment Cell Research

Volumn 6, Issue 2, 1993, Pages 61-72

  ORTONNE, JEAN‐PAUL ^a   BOSE, SUMIT KUMAR ^a  

^a PASTEUR HOSPITAL   (France)

Author keywords

5,Methoxypsoralen; Malignant Melanoma; Vitiligo

Indexed keywords

BIOLOGICAL FACTOR;

AUTOIMMUNE DISEASE; BIOLOGICAL MODEL; DISEASE MODEL; ENDOPLASMIC RETICULUM; HUMAN; IMMUNOLOGY; KERATINOCYTE; LANGERHANS CELL; MELANOCYTE; NEUROLOGIC DISEASE; PATHOLOGY; PHYSIOLOGY; REVIEW; T CELL LYMPHOMA; VITILIGO;

AUTOIMMUNE DISEASES; BIOLOGICAL FACTORS; DISEASE MODELS, ANIMAL; ENDOPLASMIC RETICULUM; HUMANS; KERATINOCYTES; LANGERHANS CELLS; LYMPHOMA, T-CELL; MELANOCYTES; MODELS, BIOLOGICAL; NERVOUS SYSTEM DISEASES; VITILIGO;

EID: 0027564749     PISSN: 08935785     EISSN: 16000749     Source Type: Journal    
DOI: 10.1111/j.1600-0749.1993.tb00584.x     Document Type: Review

References (141)

1. Evidence of Primary involvement of Keratinocytes in Vitiligo
2. Evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo
3. + T‐cells subset and evidence for peripheral T‐cell activation
4. Neuro‐ultrastructural and neuropeptide studies in vitiligo
5. Ocular abnormalities occurring with vitiligo
6. Association of IgA antimelanoma antibodies in the sera of vitiligo patients with active disease
7. Timed immunoperoxidase‐gray scale cytologie analysis correlates elevated IgA antimelanoma antibodies in vitiligo patients' sera with depigmentation
8. Factor XIIIA positive dermal dendrocytes appear abnormal in vitiligo patient skin
9. IgA can displace IgG antipigment cell antibodies from cell membrane antigens in repigmenting vitiligo
10. The detection of melanocyte autoantibodies in the Smyth Chicken model for vitiligo
11. Tyrosinase related protein‐1 is recognized by autoantibodies from vitiliginous Smyth chickens
12. Integumental pigmentary factors of lower vertebrates‐models for human hypo‐and hypermelanoses
13. S‐adenosylmethionine in skin
14. Vitiligo and the Vogt‐Koyanagi‐Harada Syndrome
15. Depigmentation: Its significance in patients with melanoma
16. Increased expression of OKM5 antigens in peripheral monocytes in vitiligo
17. Cytologic alterations in the epidermis of the depigmenting C57 BL/vit‐vit mouse
18. Langerhans' cells in vitiligo
19. Keratinocyte damage in vitiligo
20. Anti‐melanocyte autoantibodies and vitiligo
21. Persistence of abnormal melanocytes in immunosuppressed chickens of the amelanotic “DAM” line
22. Delayed‐amelanotic (DAM or Smyth) chicken: Melanocyte dysfunction in vivo and in vitro
23. Morphology of melanocytes in hair bulb and eyes of vitiligo mice
24. Animal models of an acquired pigmentary disorder‐vitiligo
25. A melanocyte‐specific, cross‐species‐reactive autoantibody is produced during onset of vitiligo in the Smyth chicken
26. Dilated rough endoplasmic reticulum and premature death in melanocytes cultured from the vitiligo mouse
27. Structural aberration of the rough endoplasmic reticulum and melanosomes compartmentalization in long‐term cultures of melanocytes from vitiligo patients
28. Expression of the barring gene in fowl: Genetic hypomelanosis
29. Fowl model for vitiligo: Genetic regulation on the fate of the melanocytes
30. Electronmicroscopy of peripheral nerve terminals and marginal melanocytes in vitiligo
31. Repigmentation of vitiliginous skin by cultured cells
32. The significance of vitiligo antibodies
33. Vitiligo and antibodies to melanocytes
34. Serum antibodies in vitiligo patients
35. Melanoma and vitiligo are associated with antibody responses to similar pigment cell antigen
36. Long‐term actinic damage in sun‐exposed vitiligo and normally pigmented skin
37. Langerhans' cell and vitiligo: Quantitative study of T6 and HLA‐DR antigen‐expressing cells
38. Ocular disturbances in vitiligo
39. Analysis of pigment cell antigens defined by vitiligo antibodies
40. Killing of melanocytes by vitiligo antibodies
41. Role of hair follicles in the repigmentation of vitiligo
42. Characterization of vitiligo antigens
43. Identification of pigment cell antigen defined by vitiligo antibodies
44. Vitiligo thyroid diseases and autoimmunity
45. Peripheral T‐cell subset imbalance in patients with vitiligo and in their apparently healthy first‐degree relatives
46. Changes in the content of adrenalin and novadrenalin in the blood of patients with vitiligo
47. Treatment of localized vitiligo by autologous minigrafting
48. Grafting and transplantation of melanocytes for repigmenting vitiligo and other types of leucoderma
49. Transplantation of in vitro‐cultured epidermis bearing melanocytes for repigmentating vitiligo
50. Treatment of refractory and stable vitiligo by transplantation of in vitro cultured epidermal autografts bearing melanocytes
51. Autologous grafting with noncultured melanocytes: A simplified method for treatment of depigmented lesions
52. Natural killer cell‐mediated cytotoxicity in vitiligo
53. Vitiligo and idiopathic guttate hypomelanosis. Repigmentation of the skin following engrafting onto nude mice
54. Regulation of human melanocyte growth, dendricity, and melanization by keratinocyte derived factors
55. Hypothesis: Symmetrical cutaneous lymphoma
56. Two views of the origin of vitiligo
57. T‐cell profiles in vitiligo
58. Mononuclear cell subpopulations and infiltrating lymphocytes in erythema dyschromiscum perstans and vitiligo
59. Epidermal changes in active vitiligo
60. Repigmentation of leukotrichia by epidermal grafting and systemic psoralen plus UVA
61. Relationship between the incidence and level of pigment cell antibodies and disease activity in vitiligo
62. Possible functional impairment of Langerhans' cells in vitiliginous skin
63. Autoimmune vitiligo. Detection of antibodies to melanin‐producing cells
64. Demonstration of tyrosinase in the vitiligo skin of human beings by a sensitive fluorometric method as well as by 14C (U)‐L‐Tyrosine incorporation into melanin
65. Ultrastructural studies of vitiligo with inflammatory raised borders
66. Modulation of melanocyte activity by acetylcholine
67. The pathological varieties of vitiligo and their response to treatment with meladinine
68. UV‐and steroid‐resistant, antigenic marker‐positive Langerhans cells increased in acute progressive phase vitiligo during PUVA and steroid therapy
69. Epidermal Langerhans' cells in various skin diseases (2) Langerhans' cells in Vitiligo
70. Depletion and repopulation of Langerhans' cells in nonsegmental type vitiligo
71. Comparison of the effect of 8‐meth‐oxypsoralen (8‐MOP) plus UVA (PUVA) on human melanocytes in vitiligo vulgaris and in vitro
72. Epidermal grafting using the tops of suction blisters in the treatment of vitiligo
73. Cytoskeletal events underlying dendrite formation in cultured pigment cells
74. Melaninanti‐korperbildung bei vitiligo
75. Uveitis caused by cytotoxic immune response to cutaneous malignant melanoma in swine: Destruction of uveal melanocytes during tumor regression
76. Loss of melanocytes in vitiligo lesions
77. Vitiligo
78. Melanomas in horses
79. A mouse model for vitiligo
80. Transplantation of human melanocytes
81. Pigment stories: From vitiligo to melanomas and points in between
82. Focal loss of pigment in the Belgian Tervuren dog
83. A genetical model for vitiligo
84. Degenerative changes of melanocytes, keratinocytes and Langerhans' cells in vitiligo
85. Successful culture of adult melanocytes obtained from normal and vitiligo donors
86. Control of melanogenesis and melanoma oncogenesis
87. Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo
88. Increased numbers of Langerhans' cells in vitiligo
89. Ultrastructural studies of vitiligo, Vogyt‐Koyangi syndrome and incontinentia‐pigmenti‐achromicans
90. Catecholamines and vitiligo
91. Urinary levels of catecholamine metabolites in children affected with vitiligo
92. Circadian rhythm of natural killer cell activity in vitiligo
93. T‐cell subpopulations in vitiligo: A chronobiologic study
94. Plasma a‐melanocyte‐stimulating hormone, b‐endorphin, met‐enkephalin, and natural killer cell activity in vitiligo
95. Antibodies to normal melanocytes in vitiligo
96. Antibodies to surface antigens of pigmented cells in animals with vitiligo
97. Antibodies to surface antigens of pigmented cells
98. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo
99. Vitiligo: Its relationship to systemic disease
100. Halo nevi and the Vogt‐Koyanagi‐Harada syndrome
101. Vitiligo, It is important
102. Dermatitis produced by applications of monobenzone in patients with active vitiligo
103. Vitiligo and depigmentation
104. Evidence for immunological mechanisms in human vitiligo: Patients' sera induce damage to human melanocytes in vitro by complement‐mediated damage and antibody‐dependent cellular cytotoxicity. J. Am. Acad
105. Audiologic disturbances in vitiligo (letter, comment)
106. Vitiligo is associated with a significant increase in HLA‐A30, Cw6 and DQw3 and a decrease in C4AQ0 in Northern Italian patients
107. Growth and regression of cutaneous melanomas in sinclair miniature swine
108. The pattern of Vogt‐Harada‐Koyanagi syndrome pigment cell antibodies corresponds to that found in vitiligo patient sera
109. Expression of nanomolar‐affinity binding sites for melatonin in Syrian hamster RPMI 1846 melanoma cells
110. A surgical treatment for vitiligo: Autologous cultured‐epithelial grafts
111. In vitro growth characteristics of melanocytes obtained from adult normal and vitiligo subjects
112. Etiology of vitiligo. A New Hypothesis
113. Alterations of cutaneous immune reactivity to dinitrofluorobenzene in graying C57 BL/vit‐vit mice
114. Vitiligo: An Immunohistological and ultrastructure study of human skin transplanted onto athymic nude mice
115. An estimate of the melanocyte mass in humans
116. Free radical reduction by thioredoxin reductase at the surface of normal and vitiliginous human keratinocytes
117. Thioredoxin reductase. Role in free radical reduction in different hypopigmentation disorders
118. Defective calcium uptake system in vitiligo
119. Thioredoxin reductase in control of the pigmentary system
120. Low catalase levels in the epidermis of patients with vitiligo
121. Vitiligo and cutaneous melanoma
122. High expression of Beta 2‐Adrenoreceptors in Vitiligo
123. Expression of cell‐cell adhesion molecules in melanocyte signaling in the white Leghorn chick embryo: An immunohistochemical and ultrastructural study
124. Hypothesis: Possible role of the melatonin receptor in vitiligo: Discussion paper
125. The DAM chicken: A model for spontaneous postnatal cutaneous and ocular amelanosis
126. Acceleration of repigmentation in vitiligo by topical minoxidil in patients on photochemotherapy
127. Melanocyte autologous grafting for treatment of leukoderma
128. Audiologic abnormalities in cases of vitiligo
129. Diminished contact sensitivity response in vitiliginous skin
130. New observations on vitiligo and ocular disease
131. Detection of antibenzene ring antibodies in patients with vitiligo
132. Vitiligo autoantibodies: Studies of subclass distribution and complement activation
133. Western blot analysis of vitiligo and alopecia areata autoantibody reactivity with cultured normal human melanocytes
134. In vitro assessment of T lymphocyte functioning in vitiligo